Table 1.
Baseline characteristics of the entire study cohort.
| Variable | (n) | (%) |
|---|---|---|
| Patients | 1338 | 100 |
| Age, years (IQR) | 56 (48–65) | |
| Sex, m/f | 819/519 | 61/39 |
| TIPS cohort | 259 | 19 |
| Covered TIPS | 177 | 68 |
| Non-covered TIPS | 82 | 32 |
| HCC | 118 | 9 |
| Underlying diseases in patients | ||
| Alcohol | 438 | 33 |
| NASH | 202 | 15 |
| HBV | 90 | 7 |
| HCV | 213 | 16 |
| Wilson disease | 8 | 1 |
| Haemochromatosis | 60 | 5 |
| Polycystic liver disease | 8 | 1 |
| Cirrhose cardiaque | 17 | 1 |
| Budd-Chiari | 13 | 0.9 |
| Portal or mesenterial vein thrombosis | 19 | 1 |
| Morbus Osler | 1 | 0.1 |
| PBC | 109 | 8 |
| SSC | 46 | 3 |
| AIH | 80 | 6 |
| PSC | 79 | 6 |
| Cryptogenic | 102 | 8 |
| CASH/DILI | 43 | 3 |
| HCC location | ||
| Left lobe | 21 | 18 |
| Right lobe | 73 | 62 |
| Bilobular | 23 | 20 |
| HCC size, cm ± SD | 5.6 ± 3.7 | n.a. |
| Laboratory parameters, median (IQR) | ||
| Serum bilirubin, mg/dl | 1.1 (0.6–2.2) | n.a. |
| INR | 1.17 (1.04–1.38) | n.a. |
| Creatinine, mg/dl | 0.9 (0.7–1.2) | n.a. |
| MELD | 11 (8–15) | n.a. |
AIH: autoimmune hepatitis; CASH: chemotherapy-associated steatohepatitis; DILI: drug induced liver injury; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HE: hepatic encephalopathy; INR: international normalized ratio; IQR: interquartile range (25–75 percentile); MELD: model of liver end-stage disease; n.a.: not analysed; NASH: non-alcoholic steatohepatitis; PBC: primary biliary cholangitis; PSC: primary sclerosing cholangitis; SD: standard deviation; SSC: secondary sclerosing cholangitis; TIPS: transjugular portosystemic shunt.